Key result
Apixaban and rivaroxaban are being compared for acute venous thromboembolism treatment, given that direct oral anticoagulants are now more commonly prescribed than vitamin K antagonists.
Key points are not available for this paper at this time.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Brady L. Stein (2019) studied this question. Apixaban and rivaroxaban are being compared for acute venous thromboembolism treatment, given that direct oral anticoagulants are now more commonly prescribed than vitamin K antagonists.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: